PDF(Pubmed)
Abstract：
BACKGROUND: In the past 50 years, human cardiovascular tissue allografts, also called homografts, have been implanted into patients with different valvular diseases. The use of these allografts and the number of cardiovascular tissue banks and their respective techniques increased. We conducted a survey to establish the quantity of allografts processed, and issued by, European tissue banks. The survey also included the collection of other relevant statistics.
METHODS: In 2011, the Foundation of European Tissue Banks collected data from 19 different cardiovascular tissue banks in 11 European countries.
RESULTS: From 2007 to 2010 the data show a decrease in the number of hearts received, from 1700 to 1640 in 18 tissue banks; the average number of hearts received for cardiovascular tissue processing decreased from 113 to 91. The number of heart valves issued for transplantation increased from 1272 in 2007 to 1486 in 2010. The average rate of discard because of microbiological contamination was 20.7%, while 4.2% of the grafts were not used because of positive serology. Half of the tissue banks issued arterial grafts, while 3 banks also issued veins and pericardium. An overview of decontamination methods shows considerable methodological differencesbetween 17 cardiovascular tissue banks.
CONCLUSIONS: From the experience in Europe, it can be concluded that cardiovascular tissue banks have an established place in the domain of cardiovascular surgery. The statistics show fluctuating data concerning the demand for human cardiovascular allografts and methodological questions. There is room for growth and improvement with respect to validation of decontamination methods.
METHODS: In 2011, the Foundation of European Tissue Banks collected data from 19 different cardiovascular tissue banks in 11 European countries.
RESULTS: From 2007 to 2010 the data show a decrease in the number of hearts received, from 1700 to 1640 in 18 tissue banks; the average number of hearts received for cardiovascular tissue processing decreased from 113 to 91. The number of heart valves issued for transplantation increased from 1272 in 2007 to 1486 in 2010. The average rate of discard because of microbiological contamination was 20.7%, while 4.2% of the grafts were not used because of positive serology. Half of the tissue banks issued arterial grafts, while 3 banks also issued veins and pericardium. An overview of decontamination methods shows considerable methodological differencesbetween 17 cardiovascular tissue banks.
CONCLUSIONS: From the experience in Europe, it can be concluded that cardiovascular tissue banks have an established place in the domain of cardiovascular surgery. The statistics show fluctuating data concerning the demand for human cardiovascular allografts and methodological questions. There is room for growth and improvement with respect to validation of decontamination methods.
摘要：
背景：在过去的50年里，人类心血管组织同种异体移植物，也称为同质移植物，已被植入不同瓣膜疾病的患者体内。这些同种异体移植物的使用和心血管组织库的数量及其各自的技术增加。我们进行了一项调查，以确定处理的同种异体移植物的数量，并由，欧洲组织银行。调查还包括收集其他相关统计数据。
方法：2011年，欧洲组织银行基金会从11个欧洲国家的19个不同的心血管组织银行收集了数据。
结果：从2007年到2010年，数据显示接受的心脏数量减少，在18个组织库中，从1700到1640；接受心血管组织处理的平均心脏数量从113减少到91。用于移植的心脏瓣膜数量从2007年的1272个增加到2010年的1486个。微生物污染的平均丢弃率为20.7%,而4.2％的移植物由于血清学阳性而未使用。一半的组织库发放了动脉移植物，而3个银行也发出静脉和心包。净化方法的概述表明，17个心血管组织库之间在方法上存在相当大的差异。
结论：从欧洲的经验来看，可以得出结论，心血管组织库在心血管外科领域具有既定的地位。统计数据显示，有关人类心血管同种异体移植物需求和方法学问题的数据波动。在净化方法的验证方面存在增长和改进的空间。
方法：2011年，欧洲组织银行基金会从11个欧洲国家的19个不同的心血管组织银行收集了数据。
结果：从2007年到2010年，数据显示接受的心脏数量减少，在18个组织库中，从1700到1640；接受心血管组织处理的平均心脏数量从113减少到91。用于移植的心脏瓣膜数量从2007年的1272个增加到2010年的1486个。微生物污染的平均丢弃率为20.7%,而4.2％的移植物由于血清学阳性而未使用。一半的组织库发放了动脉移植物，而3个银行也发出静脉和心包。净化方法的概述表明，17个心血管组织库之间在方法上存在相当大的差异。
结论：从欧洲的经验来看，可以得出结论，心血管组织库在心血管外科领域具有既定的地位。统计数据显示，有关人类心血管同种异体移植物需求和方法学问题的数据波动。在净化方法的验证方面存在增长和改进的空间。
